Freedom of information request shows Biomedical Catalyst is backing only 4% of applications assessed as worthy of funding

The Innovative Health Initiative will see the scope of joint research between industry, academics and SMEs expand beyond pharmaceuticals, to include medical technology, biotech, digital health and vaccines

AMR Action Fund will support biotechs working on later stages of clinical development, with the aim of delivering 2 - 4 new antibiotics by 2030

The University of Amsterdam (UvA)’s Faculty of Science, UvA Ventures Holding B.V. and Innovation Exchange Amsterdam (IXA-UvA) are pooling their resources to fund Macrobian Biotech BV, a single asset biotech company that will further develop medicine for the treatment of Parkinson’s disease.